|
|
Article: Guilford Licenses GPI 1485 To New Company Symphony.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Freeing its resources and staff, Guilford Pharmaceuticals Inc. licensed U.S. rights of GPI 1485 in four indications to a new entity called Symphony Neuro Development Co. (SNDC).
Receiving $43 million in capital within the last week, New York-based SNDC was formed for the sole purpose of developing the GPI 1485 programs. The funding came from Symphony Capital Partners LP, of New York.
SNDC gains rights to the product in the indications of Parkinson's disease, post-prostatectomy erectile dysfunction (PPED), HIV neuropathy and HIV-dementia. The drug is in Phase II testing in Parkinson's disease and PPED, while it's being studied at ...